Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
LONDON, BOSTON, TOKYO (December 13, 2018) – The downturn seen in the pharma and biotech sectors in the past few months of 2018 looks set to continue into 2019, with investors in the industry likely to become more cautious. According to Vantage, the independent editorial arm of Evaluate Ltd., the plus side of this could be a rallying M&A market as valuations drop, but financing will be harder to come by for those without the data to back their ideas.
As for the hottest therapy areas, 2019 will begin with the excitement around immuno-oncology, which has peaked in previous years, tempered somewhat after failures of combination therapies in 2018 – although there are still a number of combination catalysts which could reverse this sentiment. Cell and gene therapies remain popular with investors but how well untested companies hold their valuations will be a telling indicator of industry health.
“Biopharma has had a rocky few months, and many expect life to get tougher as we head into 2019,” said Amy Brown, report author. “The sector will need to deliver on its innovation promises next year if it wants to rise above wider economic and financial concerns.”
“Pharma & Biotech 2019 Preview”— Analysis Highlights:
The report, published today, offers analysis and expert commentary on M&A deals, venture financing, initial public offerings and FDA approvals. The report is based on EvaluatePharma® data.
Download the full report at: http://www.evaluate.com/PharmaBiotech2019Preview
Evaluate provides trusted commercial intelligence for the pharmaceutical industry and their advisors.
Our Evaluate platform offers unique and dynamic insights into asset risk and value alongside a seamless, comprehensive view of the pharmaceutical portfolio landscape.
Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into current and future industry developments.
Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.